Department of Obstetrics and Gynecology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
Department of Radiation Oncology, Cedars Sinai Hospital, Los Angeles, Los Angeles, CA, United States.
Front Immunol. 2022 Oct 27;13:962079. doi: 10.3389/fimmu.2022.962079. eCollection 2022.
Despite the efficacy of antiviral drug repositioning, convalescent plasma (CP), and the currently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the worldwide coronavirus disease 2019 (COVID-19) pandemic is still challenging because of the ongoing emergence of certain new SARS-CoV-2 strains known as variants of concern (VOCs). Mutations occurring within the viral genome, characterized by these new emerging VOCs, confer on them the ability to efficiently resist and escape natural and vaccine-induced humoral and cellular immune responses. Consequently, these VOCs have enhanced infectivity, increasing their stable spread in a given population with an important fatality rate. While the humoral immune escape process is well documented, the evasion mechanisms of VOCs from cellular immunity are not well elaborated. In this review, we discussed how SARS-CoV-2 VOCs adapt inside host cells and escape anti-COVID-19 cellular immunity, focusing on the effect of specific SARS-CoV-2 mutations in hampering the activation of CD8 T-cell immunity.
尽管抗病毒药物再利用、恢复期血浆 (CP) 和目前可用的针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的疫苗具有疗效,但由于某些新的 SARS-CoV-2 株不断出现,即所谓的关注变体 (VOCs),全球 2019 年冠状病毒病 (COVID-19) 大流行仍然具有挑战性。这些新出现的 VOC 中发生的病毒基因组内突变使它们能够有效地抵抗和逃避自然和疫苗诱导的体液和细胞免疫反应。因此,这些 VOC 具有更高的感染力,增加了它们在特定人群中的稳定传播,死亡率很高。虽然体液免疫逃逸过程已有详细记录,但 VOC 逃避细胞免疫的机制尚未详细阐述。在这篇综述中,我们讨论了 SARS-CoV-2 VOC 如何在宿主细胞内适应并逃避抗 COVID-19 细胞免疫,重点讨论了特定 SARS-CoV-2 突变在阻碍 CD8 T 细胞免疫激活方面的作用。
Front Immunol. 2022
J Genet Genomics. 2023-12
Int Rev Immunol. 2023
Vaccines (Basel). 2025-3-30
Front Microbiol. 2025-1-29
Virol J. 2024-12-20
Blood Sci. 2020-7-25
BMC Genomics. 2022-2-11
N Engl J Med. 2022-3-31